A Randomized, Comparative Study of Three Doses of AZD0865 and Esomeprazole for Healing of Reflux Esophagitis
Authors:
- Peter J. KahrilasPKPeter J. Kahrilas
- John DentJDJohn Dent
- Karsten LauritsenKLKarsten Lauritsen
- Peter MalfertheinerPMPeter Malfertheiner
- Hans DenisonHDHans Denison
- Stefan FranzénSFStefan Franzén
- Goran HasselgrenGHGoran Hasselgren
- 1 December 2007
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 5 (12) , 1385-1391
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Consistent inhibition of acid output with repeated dosing of AZD0865 in ratsClinical Pharmacology & Therapeutics, 2005
- AZD0865, A POTASSIUM-COMPETITIVE ACID BLOCKER (P-CAB), HAS A LONG DURATION OF EFFECT IN THE RATAmerican Journal of Gastroenterology, 2004
- New pharmacological agents for the treatment of gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 2004
- Esomeprazole (40 Mg) Compared With Lansoprazole (30 Mg) in The Treatment of Erosive EsophagitisAmerican Journal of Gastroenterology, 2002
- Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trialAmerican Journal of Gastroenterology, 2001
- Initial validation of a diagnostic questionnaire for gastroesophageal reflux diseaseAmerican Journal of Gastroenterology, 2001
- Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trialAlimentary Pharmacology & Therapeutics, 2000
- Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classificationGut, 1999
- Is a Fluoroscopic Verification of the Electrode Position Necessary in Ambulatory Intragastric pH Monitoring?Digestion, 1992
- SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPaseBiochemical Pharmacology, 1991